Quantcast

Latest IgA nephropathy Stories

2014-08-13 08:28:42

Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry...

2014-07-28 20:24:33

HAYWARD, Calif., July 28, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014. Net loss for the three months ended June 30, 2014 was $7.3 million, compared to $8.3 million for the same period in 2013. The decrease in net loss is a direct result of a decrease in interest expense in the current period. Net loss for the six months ended June 30, 2014 was $15.2 million,...

2014-07-10 04:21:24

STOCKHOLM, July 10, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon(R) issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. Nefecon is a potential disease-modifying treatment for patients with primary IgA nephropathy at risk of developing end-stage renal disease. Nefecon has shown positive results in an...

2014-05-13 08:33:02

HAYWARD, Calif., May 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the first quarter ended March 31, 2014. First Quarter 2014 Financial Results: Net loss for the first quarter ended March 31, 2014 was $7.9 million, compared to $7.6 million for the same period in 2013. Operating expenses for the three months ended March 31, 2014 increased to $7.6 million from $6.9 million in the same period of...

2014-03-12 20:24:20

HAYWARD, Calif., March 12, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013. Fourth Quarter and Fiscal Year 2013 Financial Results: Net loss for the fourth quarter and year ended December 31, 2013 was $9.2 million and $30.9 million, respectively. Operating expense for the year ended December 31, 2013 was $28.2 million as compared to $55.9 million for...

2014-01-13 04:20:59

STOCKHOLM, January 13, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon(R) (http://www.nefigan.net). Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety...

2014-01-10 08:23:12

Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below)....


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related